Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)
机构：[1]Chinese Acad Med Sci, Canc Inst & Hosp, Internal Med, Beijing, Peoples R China[2]Jilin Prov Canc Hosp, Med Oncol, Changchun, Peoples R China[3]Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China广东省人民医院[4]Peking Univ, Canc Hosp, Beijing Canc Hosp, Thorac Med Oncol, Beijing, Peoples R China[5]PLA AMMS China, Hosp 307, Med Oncol, Beijing, Peoples R China[6]Zhejiang Canc Hosp, Genet, Hangzhou, Zhejiang, Peoples R China浙江省肿瘤医院[7]Hubei Prov Tumor Hosp, Med Oncol, Wuhan, Peoples R China[8]Nanjing Mil Gen Hosp, Oncol, Nanjing, Jiangsu, Peoples R China[9]Hebei Prov Tumor Hosp, Oncol, Shijiazhuang, Peoples R China河北医科大学第四医院[10]AstraZeneca, Asia & Emerging Markets iMed, Shanghai, Peoples R China[11]Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China四川大学华西医院[12]Beijing Univ, Hosp 3, Med Oncol, Beijing, Peoples R China[13]Chinese Peoples Liberat Army Gen Hosp, Med Oncol, Beijing, Peoples R China[14]Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Peoples R China[15]Tongji Univ, Tongji Hosp, Lung Canc Oncol & Immunol, Shanghai, Peoples R China[16]Chinese Acad Med Sci, Canc Inst & Hosp, Med Oncol, Beijing, Peoples R China[17]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
第一作者机构：[1]Chinese Acad Med Sci, Canc Inst & Hosp, Internal Med, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wang J.,Cheng Y.,Wu Y-L.,et al.Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)[J].ANNALS OF ONCOLOGY.2016,27:doi:10.1093/annonc/mdw383.88.
APA：
Wang, J.,Cheng, Y.,Wu, Y-L.,An, T.,Gao, H....&Gu, Y..(2016).Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial).ANNALS OF ONCOLOGY,27,
MLA：
Wang, J.,et al."Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)".ANNALS OF ONCOLOGY 27.(2016)
医学